GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » Warby Parker Inc (NYSE:WRBY) » Definitions » Intrinsic Value: Projected FCF

Warby Parker (Warby Parker) Intrinsic Value: Projected FCF : $0.00 (As of Apr. 27, 2024)


View and export this data going back to 2021. Start your Free Trial

What is Warby Parker Intrinsic Value: Projected FCF?

Since the intrinsic value calculations based on Discounted Cash Flow Intrinsic Value: DCF (FCF Based), or Discounted Earnings Intrinsic Value: DCF (Earnings Based) cannot be applied to companies without consistent revenue and earnings, GuruFocus developed a valuation model based on normalized Free Cash Flow and Book Value of the company. The details of how we calculate the intrinsic value of stocks are described in detail here.

As of today (2024-04-27), Warby Parker's Intrinsic Value: Projected FCF is $0.00. The stock price of Warby Parker is $12.92. Therefore, Warby Parker's Price-to-Intrinsic-Value-Projected-FCF of today is 0.0.

The historical rank and industry rank for Warby Parker's Intrinsic Value: Projected FCF or its related term are showing as below:

WRBY's Price-to-Projected-FCF is not ranked *
in the Medical Devices & Instruments industry.
Industry Median: 1.67
* Ranked among companies with meaningful Price-to-Projected-FCF only.

Warby Parker Intrinsic Value: Projected FCF Historical Data

The historical data trend for Warby Parker's Intrinsic Value: Projected FCF can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Warby Parker Intrinsic Value: Projected FCF Chart

Warby Parker Annual Data
Trend Dec19 Dec20 Dec21 Dec22 Dec23
Intrinsic Value: Projected FCF
- - - - -

Warby Parker Quarterly Data
Dec19 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
Intrinsic Value: Projected FCF Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Competitive Comparison of Warby Parker's Intrinsic Value: Projected FCF

For the Medical Instruments & Supplies subindustry, Warby Parker's Price-to-Projected-FCF, along with its competitors' market caps and Price-to-Projected-FCF data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Warby Parker's Price-to-Projected-FCF Distribution in the Medical Devices & Instruments Industry

For the Medical Devices & Instruments industry and Healthcare sector, Warby Parker's Price-to-Projected-FCF distribution charts can be found below:

* The bar in red indicates where Warby Parker's Price-to-Projected-FCF falls into.



Warby Parker Intrinsic Value: Projected FCF Calculation

Since the intrinsic value calculations based on Discounted Cash Flow Intrinsic Value: DCF (FCF Based), or Discounted Earnings Intrinsic Value: DCF (Earnings Based) cannot be applied to companies without consistent revenue and earnings, GuruFocus developed a valuation model based on normalized Free Cash Flow and Book Value of the company.

The details of how we calculate the intrinsic value of stocks are described in detail here.

This method smooths out the free cash flow over the past 6-7 years, multiplies the results by a growth multiple, and adds a portion of Total Stockholders Equity.

Intrinsic Value: Projected FCF = ( Growth Multiple * Free Cash Flow (6 year avg) + 0.8 * Total Stockholders Equity (most recent) ) / Shares Outstanding (Diluted Average)

In the case of negative Total Stockholders Equity, the following formula is used (see Explanation section below for the reason):

Intrinsic Value: Projected FCF = ( Growth Multiple * Free Cash Flow (6 year avg) + Total Stockholders Equity (most recent) / 0.8 ) / Shares Outstanding (Diluted Average)



Warby Parker  (NYSE:WRBY) Intrinsic Value: Projected FCF Explanation

The growth multiple is capped between 8.35 and 17.74.

Total Stockholders Equity weighting is more art than science and it should always be revisited in more detail when researching a company. Weightings from 0% to 100% to more than 100% are possible. 80% was chosen as a happy median after taking the above ideas into consideration.

Warby Parker's Price-to-Intrinsic-Value-Projected-FCF for today is calculated as

Price-to-Intrinsic-Value-Projected-FCF=Share Price/Intrinsic Value: Projected FCF
=12.92/
=

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Warby Parker Intrinsic Value: Projected FCF Related Terms

Thank you for viewing the detailed overview of Warby Parker's Intrinsic Value: Projected FCF provided by GuruFocus.com. Please click on the following links to see related term pages.


Warby Parker (Warby Parker) Business Description

Traded in Other Exchanges
N/A
Address
233 Spring Street, 6th Floor East, New York, NY, USA, 10013
Warby Parker Inc is engaged in designing and developing designer prescription glasses and contacts to eye exams and vision tests. Brand that operates at the intersection of design, technology, healthcare, and social enterprise. The company primarily derives revenue from the sales of eyewear products, optical services, and accessories. The firm sells products and services through its stores, website, and mobile apps. Revenue generated from eyewear products includes the sales of prescription and non-prescription optical glasses and sunglasses, contact lenses, eyewear accessories, and expedited shipping charges.
Executives
Steven Clive Miller officer: Chief Financial Officer C/O WARBY PARKER INC., 233 SPRING STREET, 6TH FLOOR, NEW YORK NY 10013
David Abraham Gilboa director, officer: Co-Chief Executive Officer C/O WARBY PARKER INC., 233 SPRING STREET, 6TH FLOOR, NEW YORK NY 10013
Neil Harris Blumenthal director, officer: Co-Chief Executive Officer C/O WARBY PARKER INC., 233 SPRING STREET, 6TH FLOOR, NEW YORK NY 10013
Durable Capital Partners Lp 10 percent owner 4747 BETHESDA AVENUE, SUITE #1002, BETHESDA MD 20814
Teresa Briggs director 2225 LAWSON LANE, SANTA CLARA CA 95054
Ronald A Williams director
Jeffrey Jacob Raider director C/O WARBY PARKER INC., 233 SPRING STREET, 6TH FLOOR, NEW YORK NY 10013
Andrew Hunt director C/O ELEPHANT PARTNERS, 11 NEWBURY STREET, 5TH FLOOR, BOSTON MA 02116
D1 Capital Partners L.p. 10 percent owner 9 WEST 57TH STREET, 36TH FLOOR, NEW YORK NY 10019
Joel E Cutler director, 10 percent owner C/O GENERAL CATALYST PARTNERS, 20 UNIVERSITY ROAD, SUITE 450, CAMBRIDGE MA 02138
Youngme E Moon director 75 NETWORK DRIVE, BURLINGTON MA 01803
Daniel S. Sundheim 10 percent owner C/O D1 CAPITAL PARTNERS L.P., 9 WEST 57TH STREET, 36TH FLOOR, NEW YORK NY 10019
General Catalyst Group V Lp 10 percent owner c/o General Catalyst Group Management LL, 20 University Road Ste 450, Cambridge MA 02138
Gabrielle Sulzberger director 450 LEXINGTON AVENUE, FLOOR 13, NEW YORK NY 10017
General Catalyst Group Management Holdings, L.p. 10 percent owner 20 UNIVERSITY ROAD, 4TH FLOOR, CAMBRIDGE MA 02138